FDA Approves Imkeldi Oral Solution for the Treatment of Certain Forms of Leukemia and Other Cancers
- Shorla Oncology has announced that the U.S. Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, to treat certain forms of leukemia and other cancers, and it is designed to provide dosing accuracy.
- Imkeldi can help slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, myelodysplastic syndrome /myeloproliferative disease (MDS/MPD), and gastrointestinal tumors (GIST).
- Imatinib mesylate is a tyrosine kinase inhibitor, approved by the FDA for use in certain forms of leukemia (such as acute lymphoblastic leukemia and chronic myeloid leukemia) and other cancers in adults and pediatric patients as young as one year old. Imatinib is available both generically and as a brand name, Gleevec tablets, which were approved in 2001.
Source: Shorla Oncology
